Calreticulin arms NK cells against leukemia

Jitka Fucikova; Justin P Kline; Lorenzo Galluzzi; Radek Spisek

doi:10.1080/2162402X.2019.1671763

Calreticulin arms NK cells against leukemia

Oncoimmunology. 2019 Oct 9;9(1):1671763. doi: 10.1080/2162402X.2019.1671763. eCollection 2020.

Authors

Jitka Fucikova^{1

2}, Justin P Kline^{3

4

5}, Lorenzo Galluzzi^{6

7

8

9}, Radek Spisek^{1

2}

Affiliations

¹ Sotio, Prague, Czech Republic.
² Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
³ Deparment of Medicine, University of Chicago, Chicago, IL, USA.
⁴ Committee on Immunology, Univesity of Chicago, Chicago, IL, USA.
⁵ University of Chicago Comprehensive Cancer Center, , Chicago, IL, USA.
⁶ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
⁷ Sandra and Edward Meyer Cancer Center, New York, NY, USA.
⁸ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
⁹ Université Paris Descartes/Paris V, Paris, France.

Abstract

Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c⁺CD14⁺ cells.

Keywords: Anticancer immunity; CCR7; CD80; IL15; MHC Class II; immunogenic cell death; type I IFN.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Calreticulin / metabolism
Humans
Killer Cells, Natural / metabolism
Leukemia* / therapy
Rhabdomyosarcoma, Alveolar*

Substances

Calreticulin